Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice

Massimo Breccia, Elisabetta Abruzzese, Fausto Castagnetti, Massimiliano Bonifacio, Domenica Gangemi, Federica Sorà, Alessandra Iurlo, Luigiana Luciano, Antonella Gozzini, Massimo Gentile, Monica Bocchia, Debora Luzi, Alessandro Maggi, Nicola Sgherza, Alessandro Isidori, Monica Crugnola, Patrizia Pregno, Anna Rita Scortechini, Isabella Capodanno, Michele PizzutiRobin Foà

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32–72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.

Original languageEnglish
Pages (from-to)1577-1580
Number of pages4
JournalAnnals of Hematology
Volume97
Issue number9
DOIs
Publication statusPublished - 2018

Fingerprint

Leukemia, Myeloid, Chronic Phase
Therapeutics
ponatinib
Protein-Tyrosine Kinases

Keywords

  • Chronic myeloid leukemia
  • Ponatinib
  • Prognosis
  • Second line

ASJC Scopus subject areas

  • Hematology

Cite this

Breccia, M., Abruzzese, E., Castagnetti, F., Bonifacio, M., Gangemi, D., Sorà, F., ... Foà, R. (2018). Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. Annals of Hematology, 97(9), 1577-1580. https://doi.org/10.1007/s00277-018-3337-2

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. / Breccia, Massimo; Abruzzese, Elisabetta; Castagnetti, Fausto; Bonifacio, Massimiliano; Gangemi, Domenica; Sorà, Federica; Iurlo, Alessandra; Luciano, Luigiana; Gozzini, Antonella; Gentile, Massimo; Bocchia, Monica; Luzi, Debora; Maggi, Alessandro; Sgherza, Nicola; Isidori, Alessandro; Crugnola, Monica; Pregno, Patrizia; Scortechini, Anna Rita; Capodanno, Isabella; Pizzuti, Michele; Foà, Robin.

In: Annals of Hematology, Vol. 97, No. 9, 2018, p. 1577-1580.

Research output: Contribution to journalArticle

Breccia, M, Abruzzese, E, Castagnetti, F, Bonifacio, M, Gangemi, D, Sorà, F, Iurlo, A, Luciano, L, Gozzini, A, Gentile, M, Bocchia, M, Luzi, D, Maggi, A, Sgherza, N, Isidori, A, Crugnola, M, Pregno, P, Scortechini, AR, Capodanno, I, Pizzuti, M & Foà, R 2018, 'Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice', Annals of Hematology, vol. 97, no. 9, pp. 1577-1580. https://doi.org/10.1007/s00277-018-3337-2
Breccia, Massimo ; Abruzzese, Elisabetta ; Castagnetti, Fausto ; Bonifacio, Massimiliano ; Gangemi, Domenica ; Sorà, Federica ; Iurlo, Alessandra ; Luciano, Luigiana ; Gozzini, Antonella ; Gentile, Massimo ; Bocchia, Monica ; Luzi, Debora ; Maggi, Alessandro ; Sgherza, Nicola ; Isidori, Alessandro ; Crugnola, Monica ; Pregno, Patrizia ; Scortechini, Anna Rita ; Capodanno, Isabella ; Pizzuti, Michele ; Foà, Robin. / Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. In: Annals of Hematology. 2018 ; Vol. 97, No. 9. pp. 1577-1580.
@article{63e207a7584a4b9380078d89bac5f84b,
title = "Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice",
abstract = "Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32–72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38{\%} for primary resistance, 7{\%} for severe intolerance associated to a molecular warning, 7{\%} due to the presence of a T315I mutation, and 3{\%} for severe intolerance. Ponatinib was started at a dose of 45 mg in 60{\%} of patients, 30 mg in 38{\%}, and 15 mg in 2{\%} of patients. Overall, at a median follow-up of 12 months, 85{\%} of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.",
keywords = "Chronic myeloid leukemia, Ponatinib, Prognosis, Second line",
author = "Massimo Breccia and Elisabetta Abruzzese and Fausto Castagnetti and Massimiliano Bonifacio and Domenica Gangemi and Federica Sor{\`a} and Alessandra Iurlo and Luigiana Luciano and Antonella Gozzini and Massimo Gentile and Monica Bocchia and Debora Luzi and Alessandro Maggi and Nicola Sgherza and Alessandro Isidori and Monica Crugnola and Patrizia Pregno and Scortechini, {Anna Rita} and Isabella Capodanno and Michele Pizzuti and Robin Fo{\`a}",
year = "2018",
doi = "10.1007/s00277-018-3337-2",
language = "English",
volume = "97",
pages = "1577--1580",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice

AU - Breccia, Massimo

AU - Abruzzese, Elisabetta

AU - Castagnetti, Fausto

AU - Bonifacio, Massimiliano

AU - Gangemi, Domenica

AU - Sorà, Federica

AU - Iurlo, Alessandra

AU - Luciano, Luigiana

AU - Gozzini, Antonella

AU - Gentile, Massimo

AU - Bocchia, Monica

AU - Luzi, Debora

AU - Maggi, Alessandro

AU - Sgherza, Nicola

AU - Isidori, Alessandro

AU - Crugnola, Monica

AU - Pregno, Patrizia

AU - Scortechini, Anna Rita

AU - Capodanno, Isabella

AU - Pizzuti, Michele

AU - Foà, Robin

PY - 2018

Y1 - 2018

N2 - Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32–72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.

AB - Scarce information is available on the use of ponatinib as second-line treatment in chronic phase chronic myeloid leukemia (CP-CML) patients resistant and/or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. We collected data from 29 CML patients, with a median age of 54 years (range 32–72). Eleven patients had received dasatinib, 15 patients received nilotinib, and 3 patients received imatinib as first-line treatment. Forty-five percent of patients started ponatinib for secondary resistance, 38% for primary resistance, 7% for severe intolerance associated to a molecular warning, 7% due to the presence of a T315I mutation, and 3% for severe intolerance. Ponatinib was started at a dose of 45 mg in 60% of patients, 30 mg in 38%, and 15 mg in 2% of patients. Overall, at a median follow-up of 12 months, 85% of treated patients improved the level of response as compared to baseline, with 10 patients achieving a deep molecular response (MR4-4.5). No thrombotic events were recorded. The dose was reduced during treatment in 2 patients due to intolerance and in 8 patients in order to reduce the cardiovascular risk. Ponatinib seems a valid second-line treatment option for chronic phase CML, in particular for patients who failed a front-line second-generation TKI due to BCR-ABL-independent mechanisms of resistance.

KW - Chronic myeloid leukemia

KW - Ponatinib

KW - Prognosis

KW - Second line

UR - http://www.scopus.com/inward/record.url?scp=85045732739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045732739&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3337-2

DO - 10.1007/s00277-018-3337-2

M3 - Article

AN - SCOPUS:85045732739

VL - 97

SP - 1577

EP - 1580

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 9

ER -